Aberrant c-erbB2 expression in cell clusters overlying focally disrupted breast myoepithelial cell layers: A trigger or sign for emergence of more aggressive cell clones?

International Journal of Biological Sciences

Volumn 4, Issue 5, 2008, Pages 259-269

  Zhang, Xichen ^a   Hashemi, Shahreyar Shar ^b   Yousefi, Morvarid ^b   Ni, Jinsong ^c   Wang, Qiuyue ^a   Gao, Ling ^a   Gong, Pengtao ^a   Gao, Chunling ^d   Sheng, Joy ^e   Mason, Jeffrey ^f   Man, Yan Gao ^f  

^a JILIN UNIVERSITY   (China)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c Jilin University   (China)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e APPLIED BIOSYSTEMS   (United States)

^f ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

c erbB2; Monoclonal proliferation; Myoepithelial cells; Tumor invasion; Tumor stem cells

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST TUMOR; CELL CLONE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MYOEPITHELIUM CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA;

EID: 50449095904     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4.259     Document Type: Article

References (56)

1. Tsubura A., Shikata N., Inui T., et al. Immunohistochemical localization of myoepithelial cells and basement membrane in normal, benign and malignant human breast lesions. Virch Arch. 1998; 413: 133-9.
2. Guelstein VI, Tchypysheva TA, Ermilova VD, et al. Myoepithelial and basement membrane antigens in benign and malignant human breast tumors. Int J Cancer. 1993; 53: 269-77.
3. Clarke R, Brunner N, Katzenellenbogen BS. Progression of human breast cancer cells from hormone- dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA. 1989; 86:3649-53.
4. Goldfarb RH, Liotta LA. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost. 1986; 12:294-307.
5. Doffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: roles in breast carcinogenesis and metastasis. Breast Cancer Res. 2000; :252-7.
6. Moinfar F, Man YG, Bratthauer GL, et al. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (Clinging ductal carcinoma in situ)-A simulator of normal mammary epithelium. Cancer. 2000; 88:2072-81.
7. Deng G, Liu Y, Ziotnikov G, et al. Loss of heterogosity in normal tissue adjacent to breast carcinomas. Science. 1996; 274 (5295): 2057-9.
8. Man YG, Nieburgs HE. A subset of cell clusters with malignant features in morphologically normal and hyperplastic breast tissues. Cancer Detect Prev. 2006; 30 (3): 239-47.
9. Man YG. Bad seeds produce bad crops:a single step-process of breast carcinogenesis and progression. Bioscience Hypotheses; In press.
10. Page DL, Duppont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer. 1982; 49:751-8.
11. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continues local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995; 76:1197-2000.
12. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trial and tribulations. Science. 2002; 295 (5564):2387-92.
13. [Internet] Bethesda, MD: National Cancer Institute, NIH, DHHS. Cancer Trends Progress Report - 2005 Update. http://progressreport.cancer.gov.
14. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Nat Cancer Inst. 2004; 96: 906-20.
15. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 1994; 263: 526-9.
16. Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 2001; 25:1954-60.
17. Sternlight MD, Barsky SH. The myoepithelial defense: a host defense against cancer. Med Hypotheses. 1997; 48:37-46.
18. Zhang R, Man YG, Vang RS, et al. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res. 2003; 5: R151-6.
19. Man YG, Tai L, Barner R, Vang R, et al. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res. 2003; 5: R231-41.
20. Man YG, Sang QXA. The significance of focal myoepitehlial cell layer disruptions in breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis. Exp Cell Res. 2004; 301:103-18.
21. Man YG, Zhang Y, Shen T, et al. cDNA expression profiling identifies elevated expressions of tumor progression and invasion related genes in cell clusters of in situ breast tumors. Breast Cancer Res Treat. 2005; 89:199-208.
22. Yousefi M, Mattu R, Gao C, Man YG. Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: Implications for tumor progression and invasion. Appl Immunohistochem Mol Morphol. 2005; 13:30-7.
23. Man YG, Shen T, Weisz J, et al. A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. Cancer Detect Prev. 2005; 29:323-31.
24. Man YG, Zhao CQ, Wang J. Breast tumor cell clusters and their budding derivatives show different immunohistochemical profiles during stromal invasion: implications for hormonal and drug therapies. Cancer Therapy. 2006; 4:193-204.
25. Man YG. Focal degeneration of aged or injured myoepithelial cells and the resultant auto- immunoreactions are trigger factors for breast tumor invasion. Medical Hypotheses. 2007; 69(6): 1340-57.
26. Zhang XC, Hashemi SS, Yousefi M, et al. Atypical expression of e-cadherin in cell clusters overlying focally disrupted mammary myoepithelial cell layers: implications for tumor cell motility and invasion. Cancer Biomarkers. Pathol-Res Pract, conditionally accepted
27. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61(Suppl 2):1-13.
28. Cooke T, Reeves J, Lanigan A, Stanton O. HER2 as a prognostic and predicative marker for breast cancer. Ann Oncol. 2001; 12 (Suppl 2): S23-8.
29. Menard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001; 12 (Suppl 1): S15-9.
30. Tavassoli FA, Man YG. Morphofunctional features of intraductal hyperplasia, atypical hyperplasia, and various grades of intraductal carcinoma. The Breast J. 1995; 1(3):155-62.
31. Man YG, Tavassoli FA. A simple epitope retrieval method without the use of microwave oven or enzyme digestion. Appl Immunohistochem. 1996; 4(2):139-41.
32. Man YG, Burgar A. An antigen unmasking protocol that satisfies both immunohistochemical and subsequent molecular biological assessments. Pathol-Res Pract. 2003; 199: 815-25.
33. Bustin SA, Nolan T. Data analysis and interpretation. In: Busti SA (ed) A-Z of quantitative PCR, pp441-492. International University Line, La Jolla, CA, USA. 2004.
34. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a pratical alternative for fluorescence in situ hybridization to detect HER-s/neu oncogene amplification in achival breast cancer samples. Am J Pathol. 2000; 157:1467-72.
35. Klos KS, Wyszomierski SL, Sun M et al. c-erbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 2006; 64: 2028-37.
36. Jackson-Fisher AJ, Bellinger G, Ramabhadran R, et al. ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci USA. 2004; 101(49):17138-43.
37. Niemann C, Brinkmann V, Spitzer E, et al. Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol. 1998; 143(2):533-45.
38. Shyamala G, Chou YC, Cardiff RD, Vargis E. Effect of c-neu/ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: Implications for breast cancer biology. Cancer Res. 2006; 66(21):10391-8.
39. Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol. 2005; 124: S16-28.
40. Chakravarthy MV, Spangenhurg EE, Booth FW. Culture in low levels of oxygen enhances in vitro proliferation potential of satellite cells from old skeletal muscles. Cell Mol Life Sci. 2001;58:1150-8.
41. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumor-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003; 3(6): 411-21.
42. Zhu G, Reynolds L, Crnogorac-Jurceic T, et al. Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells of breast cancer. Oncogene. 2003; 22:3742-48.
43. Madson JG, Lynch DT, Tinkum KL, et al. Erbb2 regulates inflammation and proliferation in the skin after ultraviolet irradiation. Am J Pathol. 2006; 169(4):1402-14.
44. Darcy KM, Zangani D, Wohlbueter AL, et al. Changes in ErbB2 (her-2/neu), Erbb3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. J Histochem Cytochem. 2000; 48(1):63-8.
45. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest. 1994; 70: 6-22.
46. Azzopardi JG. Problems in breast pathology. Landon: WB Saunders. 1979.
47. Malins DC, Johnson PM, Barker EA. Cancer-related changes in prostate DNA as men age and early identification of metastasis in prostate tumors. Proc Natl Acad Sci USA. 2003; 100:5401-6.
48. Malins DC, Anderson KM, Gilman NK. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci Sci USA. 2004; 101:10721-5.
49. Malins DC, Gilman NK, Green VM. A DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA 2005; 102: 19093-6.
50. Soumana SO, Aller P, Garnier N, Genest M. Transmembrane peptides from tyrosine kinase receptor. Mutation-related behavior in a lipid bilayer investigated by molecular dynamics simulations. J Biomol Struct Dyn. 2005; 23(1):91-100.
51. Garnier N, Genest D, Hebert E, Genest M. Influence of a mutation in the transmembranr domain of the p185c-erbB2 oncogene-encoded protein studied by molecular dynamics simulations. J Biomol Struct Dyn. 1994; 11(5):983-1002.
52. Weiner DB, Liu J, Cohen JA, et al. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature. 1989; 339(6221):230-1.
53. Taylor SL, Platt-Higgins A, Rudland PS, Winstanley JH, Barraclough R. Cytoplasmic staining of c- erbB2 is not associated with the presence of detectable c-erbB2 mRNA in breast specimens. Int J Cancer. 1998; 76(4):459-63.
54. Taylor SL, Rudland PS, Barraclough R. C-erbN-2 mRNA in breast cancer specimens that exhibit membrane or cytoplasmic immunoreactivity for c-erbB-2. Oncol Res. 1999; 11(7):311-7.
55. Keshgegian AA, Cnaan A. erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. Am J Clin Pathol. 1997; 108(4):456-63.
56. Lambropoulou M, Stefanou D, Alexiadis G, Tamiolakis D, Tripsisnis G, Chatzaki E, et al. Cytoplasmic expression of c-erb-B2 in endometrial carcinomas. Onkologie. 2007; 30(10):495-500.